Clinical Trials Logo

Hematologic Malignancies clinical trials

View clinical trials related to Hematologic Malignancies.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06465433 Not yet recruiting - Clinical trials for Hematologic Malignancies

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Start date: June 18, 2024
Phase: Phase 2
Study type: Interventional

This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..

NCT ID: NCT06455553 Not yet recruiting - Clinical trials for Hematologic Malignancies

Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L.

VISCOTHEM-1
Start date: June 17, 2024
Phase: N/A
Study type: Interventional

The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is to evaluate the interpretability of viscoelastic tests (Quantra® and ROTEM® type) in relation to platelet levels measured in standard biology in patients with haematological malignancies, hospitalized in day hospitals or full hematology wards, presenting thrombocytopenia strictly below 50 G/L. Participants will undergo an additional blood sample to standard care. The total volume of blood drawn will be 12.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen.

NCT ID: NCT06378138 Not yet recruiting - Clinical trials for Hematologic Malignancies

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start date: April 25, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT ID: NCT06296368 Not yet recruiting - Multiple Myeloma Clinical Trials

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

DISCOVERY
Start date: September 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatment decisions compared to usual care.

NCT ID: NCT05028478 Not yet recruiting - Clinical trials for Hematologic Malignancies

A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Start date: October 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor activity of CN202 in adult subjects with locally advanced or metastatic solid tumor or hematologic malignancies

NCT ID: NCT02386332 Not yet recruiting - Clinical trials for Hematologic Malignancies

A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies

Start date: March 2015
Phase: Phase 3
Study type: Observational

This is an open-label, prospective, observational, multicenter, randomized study to compare the efficacy between unrelated umbilical cord blood transplantation (UCBT) and HLA-haploidentical related hematopoietic stem cell transplantation ,after myeloablative conditioning for adult patients with hematologic malignancies.